Acquisition of CorHepta - Schedule of Allocation of Consideration Transferred (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Feb. 21, 2025 |
Dec. 31, 2025 |
|
| Fair Value, Recurring | ||
| Business Combination [Line Items] | ||
| Fair value of consideration | $ 7,338,719 | |
| CorHepta Pharmaceuticals [Member] | ||
| Business Combination [Line Items] | ||
| Cash | 49,633 | |
| Current liabilities | 68,208 | |
| Fair value of consideration | 7,400,000 | |
| CorHepta Pharmaceuticals [Member] | Fair Value, Recurring | ||
| Business Combination [Line Items] | ||
| Fair value of consideration | $ 7,338,719 | |
| CorHepta Pharmaceuticals [Member] | In Process Research and Development | ||
| Business Combination [Line Items] | ||
| Acquired IPR&D | $ 7,357,294 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liability assumed in business combination and recognized at acquisition date, classified as current. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|